Retatrutide
Retatrutide is an investigational synthetic peptide and a first-in-class triple-hormone-receptor agonist designed for the treatment of obesity and type 2 diabetes. It mimics the actions of three natural gut hormones: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon.
Price range: $95.99 through $299.99
For research use only. Not for human consumption. Not FDA approved.
About this compound
Retatrutide (LY3437943) is an investigational synthetic peptide functioning as a first-in-class triple agonist at GLP-1, GIP, and glucagon receptors simultaneously. Its tripartite receptor activity profile distinguishes it from dual-agonist compounds and makes it a subject of active investigation in metabolic receptor pharmacology.
Compound Specifications
- Molecular Weight: ~4,718 Da
- CAS: 2381090-38-4
- Purity: ≥99.002–99.569% by lot (HPLC + MS verified)
- Form: Lyophilized powder
- Storage: −20°C, protected from light and moisture
- Reconstitution: Bacteriostatic water or sterile water
- Available sizes: 10mg, 20mg, 50mg, 60mg
Research Context
Research applications include comparative receptor agonism studies, energy expenditure modeling, and investigation of tripartite incretin-glucagon axis interactions. Batch-specific COAs available for each size.
For research and laboratory use only. Not for human or animal consumption. Research Use Only.




